Press Release – New York, NY – December 30, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm has represented OWC Pharmaceutical Research Corp. (OTCQB: OWCP) (the “Company”), a company focused on discovering, developing and commercializing cannabis-based novel therapeutics and treatments, in connection with a $37,500 convertible note and $750,000 equity purchase agreement with Kodiak Capital Group, LLC., a California-based institutional investor (“Kodiak”). The Company has agreed to file a registration statement with the SEC covering the shares issuable upon conversion of the note and the shares that may be issued to Kodiak under the terms of the agreement. After the SEC has declared the registration statement related to the transaction effective, the Company will have the right at its sole discretion to sell up to $750,000 of common stock under the terms set forth in the agreement. The Sichenzia Ross Friedman Ference LLP team was led by partners Marc Ross and James Turner and associate Avital Even-Shoshan.
- Sichenzia Ross Ference Carmel LLP Represents Safe & Green Holdings Corp. in a $8.0 Million Private Placement - April 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents FatPipe, Inc. in Closing of $4 Million Initial Public Offering - April 10, 2025
- Sichenzia Ross Ference Carmel Names Matilde Tysz as Chief Strategy Officer - April 9, 2025
